[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100617832":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":23,"locations":29,"responsibleParty":57,"collaborators":61,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":67,"sex":73,"minAge":74,"maxAge":22,"enrollmentInfo":75,"targetDuration":22,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":84,"overallStatus":32,"whyStopped":22,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"Universiti Sains Malaysia","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Mobithron Advance Arm","EXPERIMENTAL","Treatment Arm will receive one Mobithron Advance oral tablet daily for 12 months. Outcomes will be assessed include cartilage preservation (MRI), pain (VAS), function (WOMAC), and safety (renal function and adverse events)",[13],"Drug: Type 2 collagen",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Type 2 collagen","This study's intervention is undenatured type II collagen (UC-II) oral tablets, one daily for 12 months, targeting knee osteoarthritis (KL grade 1-3). It differs from other interventions such as glucosamine, chondroitin, hyaluronic acid, or NSAIDs by working through an oral tolerance mechanism with the potential to preserve cartilage and modify disease progression, rather than providing only short-term symptom relief.",[9],[21],"Mobithron Advance",null,[24],{"name":25,"role":26,"phone":27,"phoneExt":22,"email":28},"Mohamad Anas Alfian Bin Sufri Dr., Medicine and Surgery","CONTACT","+60192993482","anas.alfian92@gmail.com",[30],{"facility":31,"status":32,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Hospital Univerisiti Sains Malaysia (HUSM)","RECRUITING","Kota Bharu","Kelantan","16150","Malaysia","MY",{"type":39,"coordinates":40},"Point",[41,42],102.24333,6.12361,{"lat":42,"lon":41},[45,49,52,55],{"name":46,"role":26,"phone":47,"phoneExt":22,"email":48},"Amran A Shokri Prof. Dr, master in orthopedics","+60 12-900 9272","amrankb@usm.my",{"name":50,"role":26,"phone":51,"phoneExt":22,"email":22},"Mohammad Anas Alfian Bin Sufri Dr., Bachelor of Medicine & Surgery","+60 19-299 3482",{"name":53,"role":54,"phone":22,"phoneExt":22,"email":22},"Muhammad Rajaei Ahmad @ Mohd Zain","SUB_INVESTIGATOR",{"name":56,"role":54,"phone":22,"phoneExt":22,"email":22},"Fattah Rahiman Ghazali",{"type":58,"investigatorFullName":59,"investigatorTitle":60,"investigatorAffiliation":5,"oldNameTitle":22,"oldOrganization":22},"PRINCIPAL_INVESTIGATOR","Amran Ahmed Shokri","Professor",[62],{"name":63,"class":64},"BREGO Life Sciences Sdn Bhd","INDUSTRY","100617832","early-phase-1-long-term-effects-of-mobithron-advance-on-knee-osteoarthritis-aims-to-investigate-the-effects-of-mobithron-advance-on-oa-progression-100617832",false,"NCT07323745","Long-Term Effects of Mobithron Advance on Knee Osteoarthritis Aims to Investigate the Effects of Mobithron Advance on OA Progression","Long-Term Effects of Mobithron Advance on Knee Osteoarthritis","mobithron adv","Inclusion Criteria:\n\n* Males and female patients above 50 years old at the time of recruitment.\n* OA Diagnosis: Patients with one or both knee osteoarthritis according to clinical and radiological criteria of the American College of Rheumatology (ACR).\n* OA Grade: Kellgren Lawrence grade 1-3\n\nExclusion Criteria:\n\n* Secondary arthritis (e.g., rheumatoid arthritis, psoriatic arthritis).\n* History of joint surgery.\n* Patients who received steroid injection treatment within the last 3 months or hyaluronic acid injection treatment within the last 6 months.\n* Contraindications to Mobithron Advance (e.g., known allergies, severe liver or kidney disease).\n* Patients planning for knee surgery within the research period.\n* Patients on pharmacological treatment for osteoarthritis, other than rescue analgesic agent, e.g: glucosamine, chondroitin, oral steroid","ALL","50 Years",{"count":76,"type":77},84,"ESTIMATED","INTERVENTIONAL",[80],"EARLY_PHASE1","The goal of this clinical trial is to learn if the Mobithron Advance drug works to treat and slow the progression of osteoarthritis (OA) in patients. It will also learn about the safety and long-term effects of this drug. The main questions it aims to answer are:\n\n* Does long-term administration of Mobithron Advance can modify the progression of knee osteoarthritis with Kellgren-Lawrence grade 1 to 3 in HUSM patients?\n* Does long term usage of Mobithron Advance has safety profile? Researchers will compare the Mobithron Advance drug to a placebo (a look-alike substance that contains no drug) to see if said drug works to treat OA.\n\nParticipants will:\n\n* Undergo pre-study assessment (baseline assessments) during first visit\n* Take oral Mobithron Advance daily for 1 year\n* Visit the clinic once at 3 months, 6 months and 12 months intervals from the initial visit for follow up assessments",[83],"Osteoarthritis (OA) of the Knee",[21],"2026-06-09",{"date":87,"type":88},"2026-06-12","ACTUAL",{"date":90,"type":88},"2026-05-03",{"date":92,"type":77},"2027-10-31",{"name":5,"class":6},1]